▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the risk of ergotism when given withergometrine.
rTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the risk of ergotism when given withergotamine.
rTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toerlotinib.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the concentration ofeverolimus. Avoid or adjust
dose.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tofesoterodine. Adjustfesoterodine
dose with moderate inhibitors of CYP3A4 in hepatic and renal
impairment.nStudy
▶Verapamilis predicted to increase the exposure tofidaxomicin.
Avoid.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tofingolimod. Avoid.o
Theoretical→Also seeTABLE 6p. 848
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure togefitinib.oTheoretical
▶Grapefruit juicevery slightly increases the exposure to
amlodipine. Avoid.nStudy
▶Grapefruit juiceincreases the exposure tocalcium channel
blockers(nifedipine, verapamil). Avoid.nStudy
▶Grapefruit juiceincreases the exposure tofelodipine. Avoid.
oStudy
▶Grapefruit juiceis predicted to increase the exposure to
lercanidipine. Avoid.oTheoretical
▶Grapefruit juiceincreases the exposure tonicardipine.n
Study
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the concentration ofguanfacine. Adjustguanfacine
dose,p. 231.oTheoretical→Also seeTABLE 8p. 848
▶H 2 receptor antagonists(cimetidine)(high-dose) are predicted to
increase the exposure tolercanidipine.oTheoretical
▶H 2 receptor antagonists(cimetidine)moderately increase the
exposure tonifedipine. Monitor and adjust dose.rStudy
▶H 2 receptor antagonists(cimetidine)increase the exposure to
verapamil.oStudy
▶H 2 receptor antagonists(cimetidine)slightly increase the
exposure tocalcium channel blockers(diltiazem, nimodipine).
Monitor and adjust dose.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tocalcium channel blockers(amlodipine, felodipine, lacidipine,
nicardipine, nifedipine, nimodipine). Monitor and adjust dose.
oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tocalcium channel blockers(diltiazem, verapamil).rStudy
▶HIV-protease inhibitorsare predicted to markedly increase the
exposure tolercanidipine. Avoid.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toibrutinib. Adjustibrutinibdose with
moderate inhibitors of CYP3A4.rStudy
▶Idelalisibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine, nicardipine,
nifedipine, nimodipine). Monitor and adjust dose.o
Study
▶Idelalisibis predicted to increase the exposure tocalcium
channel blockers(diltiazem, verapamil).rStudy
▶Idelalisibis predicted to markedly increase the exposure to
lercanidipine. Avoid.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toimatinib.oTheoretical
▶Imatinibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toivabradine. Avoid.oStudy→
Also seeTABLE 6p. 848
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toivacaftor. Adjustivacaftordose with
moderate inhibitors of CYP3A4,p. 186.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tolapatinib.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the risk of neurotoxicity when given withlithium.
rAnecdotal
▶Calcium channel blockers(amlodipine, lacidipine)are predicted
to increase the exposure tolomitapide. Separate
administration by 12 hours.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tolomitapide. Avoid.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tolurasidone.oStudy→Also see
TABLE 8p. 848
▶Macrolides(clarithromycin)are predicted to markedly increase
the exposure tolercanidipine. Avoid.rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure todiltiazem.rTheoretical
▶Macrolides(erythromycin)are predicted to increase the
exposure toverapamil.rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure tocalcium channel blockers(amlodipine, felodipine,
lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine).
Monitor and adjust dose.oStudy
▶Macrolides(clarithromycin)are predicted to increase the
exposure tocalcium channel blockers(amlodipine, felodipine,
lacidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Macrolides(clarithromycin)are predicted to increase the
exposure tocalcium channel blockers(diltiazem, verapamil).
rStudy
▶Intravenousmagnesiumpotentially increases the risk of
hypotension when given withcalcium channel blockers
(amlodipine, clevidipine, felodipine, lacidipine, lercanidipine,
nicardipine, nifedipine, nimodipine, verapamil)(in pregnant
women).rAnecdotal
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tomidazolam. Monitor side effects and
adjust dose.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tomidostaurin.oTheoretical
▶Mitotaneis predicted to decrease the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nimodipine). Monitor and adjust
dose.oStudy
▶Monoclonal antibodies(tocilizumab)are predicted to decrease
the exposure tocalcium channel blockers. Monitor and adjust
dose.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tonaloxegol. Adjustnaloxegoldose and
monitor side effects.oStudy
▶Netupitantis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Nevirapineis predicted to decrease the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oTheoretical
▶Nevirapineis predicted to decrease the exposure tocalcium
channel blockers(diltiazem, verapamil).oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tonilotinib.oTheoretical
▶Nilotinibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Verapamilis predicted to increase the exposure tonintedanib.
oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toolaparib. Avoid moderate inhibitors
of CYP3A4 or adjustolaparibdose.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toopioids(alfentanil, buprenorphine,
fentanyl, oxycodone). Monitor and adjust dose.o
Study→Also seeTABLE 6p. 848
BNFC 2018 – 2019 Calcium channel blockers—Calcium channel blockers 891
Interactions
|Appendix 1
A1